OBJECTIVE:To examine Hedan tablet(HDT,荷丹片)'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet(HFD),as well as its regulatory effects and primary active constituents.METHODS:By using ultra-...OBJECTIVE:To examine Hedan tablet(HDT,荷丹片)'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet(HFD),as well as its regulatory effects and primary active constituents.METHODS:By using ultra-performance liquid chromatography(UPLC)-quadrupole-time-of-flight(QTOF)-tandem mass spectrometry(MS/MS),the components of HDT that can enter the circulatory system were found,aiming to investigate its active constituents with pharmacological effects.Based on network pharmacology approaches,the relevant HDT targets in the therapy of hyperlipidemia were anticipated.The possible mechanism of HDT for hyperlipidemia treatment was verified by in-vivo experiments,and the main active components of HDT for hyperlipidemia treatment were analyzed via in-vitro experiments.RESULTS:UPLC-QTOF-MS/MS identified 30 components of HDT entering the circulatory system,primarily consisting of flavonoids,diterpenoids and alkaloids.The results of a network pharmacology study revealed that 30 active components mostly target 74 genes associated with hyperlipidemia.The primary active ingredients may include quercetin,kaempferol,and epicatechin,and the main gene targets may be tumor necrosis factor(TNF),interleukin-6(IL-6),interleukin 1 beta(IL-1β),etc.The results of animal experiments demonstrated that HDT can significantly regulate the blood lipid level in rats with HFD,improve the degree of inflammatory infiltration in rat liver cells,lower TNF-α,Creactive protein(CRP),IL-6,matrix metalloproteinase 9(MMP9) and malondialdehyde(MDA) levels while raising total superoxide dismutase(T-SOD) level.Meanwhile,HDT can considerably lower the expression of sterol regulatory element-binding transcription factor 2(SREBF2),3-hydroxy-3-methylglutaryl-CoA reductase(HMGCR),and MMP9 while significantly increasing the expression of peroxisome proliferator-activated receptor alpha(PPAR-α) and PPAR-γ.In vitro study confirmed that quercetin and kaempferol could reduce the levels of IL-6,IL1B,MMP9 and HMGCR in the high-fat model of hepatoma G2 cells.CONCLUSIONS:The mechanism by which HDT treats hyperlipidemia involves modification of the lipid metabolism targets such as downregulating SREBF2,HMGCR and MMP9,and upregulating PPAR-α and PPAR-γ,as well as anti-inflammatory and antioxidant actions.This study provides a pharmacological and biological rationale for the use of HDT in clinical hyperlipidemia management.展开更多
目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为...目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为慢性心力衰竭的住院患者的病历,按照纳入和排除标准,利用中医传承辅助平台(Traditional Chinese Medicine Inheritance Computer System,TCMICS)V3.0对中药使用频次、用药规律等进行分析;采用网络药理学的方法,筛选出核心药物组合治疗CHF的潜在靶点,初步预测其可能的作用机制。结果共纳入625例患者,787张中药处方。有56味中药使用频次超过50次,主要为补虚药、利水渗湿药及活血化瘀药;结合高频中药、关联规则及聚类分析得到治疗CHF的核心药物组合为:黄芪、党参、茯苓、桂枝、益母草、川芎和赤芍。网络药理学分析表明核心药物组合中槲皮素、异鼠李素等活性成分作用于AKT1、EGFR、MMP9等20个CHF核心靶点;核心药物组合治疗CHF的潜在靶点主要富集在11个细胞组成、17种分子功能和20个生物过程中;生物学通路主要为MAPK信号通路、PI3K-Akt信号通路、AMPK信号通路等。结论中药治疗CHF以益气温阳,利水消肿,活血化瘀为主。核心药物组合可能通过参与心室重塑、炎症反应等过程从而发挥治疗CHF的作用。展开更多
目的:观察富血小板血浆(Platelet-rich Plasma,PRP)联合热敏灸治疗慢性局限性湿疹的临床疗效,初步明确治疗机制。方法:将80例慢性局限性湿疹患者随机分为对照组与治疗组各40例,对照组采用复方氟米松软膏治疗;治疗组采用PRP联合热敏灸治...目的:观察富血小板血浆(Platelet-rich Plasma,PRP)联合热敏灸治疗慢性局限性湿疹的临床疗效,初步明确治疗机制。方法:将80例慢性局限性湿疹患者随机分为对照组与治疗组各40例,对照组采用复方氟米松软膏治疗;治疗组采用PRP联合热敏灸治疗,两组均治疗21 d。比较两组患者治疗前、治疗后第1天及治疗后第60天皮损,包括不同部位皮损症状严重程度,所占面积的大小、瘙痒程度进行综合评分,取湿疹面积及严重程度指数(Eczema Area and Severity Index,EASI)评分和视觉模拟评分法(Visual Analogue Scale,VAS)评分的总和评分进行疗效评价。结果:两组治疗后第1天各皮损项目评分较治疗前下降(P<0.05),治疗组各皮损项目评分下降幅度优于对照组(P<0.05);治疗组治疗后第60天各皮损项目评分较治疗前仍有明显下降(P<0.05),对照组各皮损项目评分较治疗前无明显下降(P>0.05);治疗组近期、远期疗效总有效率均高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:PRP联合热敏灸治疗能够在行气通络、活血除湿的同时起到促进组织修复,加速疮面愈合,抗炎抗菌的作用,显著降低慢性局限性湿疹皮损评分,改善皮损症状,且复发率低、治疗时间短、经济负担小,可有效改善患者的生活质量,值得临床进一步推广。展开更多
基金the National Natural Science Foundation of China:Effects of Hawthorn Leaves Flavonoids on Atherosclerosis Unstable Plaques based on the Mechanism of Liver-gut axis Liver X Receptor (LXR-a)-mediated Iron and Lipid Metabolism Disorders (No.82260794)the Natural Science Foundation of Jiangxi Province:based on Secreted Phospholipase A2 TypeⅡA (sPLA2-ⅡA) Regulating Lipid Mediated Foam Cell Formation to Explore the Effect and Molecular Mechanism of Hawthorn Leaf Flavonoids on Antiatherosclerosis (No.20212BAB206013)+1 种基金the Key R&D Program of Jiangxi Province:Research on the Quality Enhancement and Industrialization Technology Improvement of the Lipid-Lowering Traditional Chinese Medicine"Hedan Tablet"(No.20201BBG71005)Science and Technology Project of Jiangxi Provincial Department of Education:based on the"Phlegm-Stasis"Theory to Explore the Effects and Molecular Mechanisms of Hawthorn Leaves Flavonoids on Improving Iron and Lipid Metabolism Disorders in Atherosclerosis (No.GJJ2203502)。
文摘OBJECTIVE:To examine Hedan tablet(HDT,荷丹片)'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet(HFD),as well as its regulatory effects and primary active constituents.METHODS:By using ultra-performance liquid chromatography(UPLC)-quadrupole-time-of-flight(QTOF)-tandem mass spectrometry(MS/MS),the components of HDT that can enter the circulatory system were found,aiming to investigate its active constituents with pharmacological effects.Based on network pharmacology approaches,the relevant HDT targets in the therapy of hyperlipidemia were anticipated.The possible mechanism of HDT for hyperlipidemia treatment was verified by in-vivo experiments,and the main active components of HDT for hyperlipidemia treatment were analyzed via in-vitro experiments.RESULTS:UPLC-QTOF-MS/MS identified 30 components of HDT entering the circulatory system,primarily consisting of flavonoids,diterpenoids and alkaloids.The results of a network pharmacology study revealed that 30 active components mostly target 74 genes associated with hyperlipidemia.The primary active ingredients may include quercetin,kaempferol,and epicatechin,and the main gene targets may be tumor necrosis factor(TNF),interleukin-6(IL-6),interleukin 1 beta(IL-1β),etc.The results of animal experiments demonstrated that HDT can significantly regulate the blood lipid level in rats with HFD,improve the degree of inflammatory infiltration in rat liver cells,lower TNF-α,Creactive protein(CRP),IL-6,matrix metalloproteinase 9(MMP9) and malondialdehyde(MDA) levels while raising total superoxide dismutase(T-SOD) level.Meanwhile,HDT can considerably lower the expression of sterol regulatory element-binding transcription factor 2(SREBF2),3-hydroxy-3-methylglutaryl-CoA reductase(HMGCR),and MMP9 while significantly increasing the expression of peroxisome proliferator-activated receptor alpha(PPAR-α) and PPAR-γ.In vitro study confirmed that quercetin and kaempferol could reduce the levels of IL-6,IL1B,MMP9 and HMGCR in the high-fat model of hepatoma G2 cells.CONCLUSIONS:The mechanism by which HDT treats hyperlipidemia involves modification of the lipid metabolism targets such as downregulating SREBF2,HMGCR and MMP9,and upregulating PPAR-α and PPAR-γ,as well as anti-inflammatory and antioxidant actions.This study provides a pharmacological and biological rationale for the use of HDT in clinical hyperlipidemia management.
文摘目的基于数据挖掘方法总结中药治疗慢性心力衰竭(chronic heart failure,CHF)的用药规律,利用网络药理学方法对核心药物组合治疗CHF的活性成分和作用机制进行初步预测。方法收集2014年1月至2021年6月中国中医科学院西苑医院第一诊断为慢性心力衰竭的住院患者的病历,按照纳入和排除标准,利用中医传承辅助平台(Traditional Chinese Medicine Inheritance Computer System,TCMICS)V3.0对中药使用频次、用药规律等进行分析;采用网络药理学的方法,筛选出核心药物组合治疗CHF的潜在靶点,初步预测其可能的作用机制。结果共纳入625例患者,787张中药处方。有56味中药使用频次超过50次,主要为补虚药、利水渗湿药及活血化瘀药;结合高频中药、关联规则及聚类分析得到治疗CHF的核心药物组合为:黄芪、党参、茯苓、桂枝、益母草、川芎和赤芍。网络药理学分析表明核心药物组合中槲皮素、异鼠李素等活性成分作用于AKT1、EGFR、MMP9等20个CHF核心靶点;核心药物组合治疗CHF的潜在靶点主要富集在11个细胞组成、17种分子功能和20个生物过程中;生物学通路主要为MAPK信号通路、PI3K-Akt信号通路、AMPK信号通路等。结论中药治疗CHF以益气温阳,利水消肿,活血化瘀为主。核心药物组合可能通过参与心室重塑、炎症反应等过程从而发挥治疗CHF的作用。
文摘目的:观察富血小板血浆(Platelet-rich Plasma,PRP)联合热敏灸治疗慢性局限性湿疹的临床疗效,初步明确治疗机制。方法:将80例慢性局限性湿疹患者随机分为对照组与治疗组各40例,对照组采用复方氟米松软膏治疗;治疗组采用PRP联合热敏灸治疗,两组均治疗21 d。比较两组患者治疗前、治疗后第1天及治疗后第60天皮损,包括不同部位皮损症状严重程度,所占面积的大小、瘙痒程度进行综合评分,取湿疹面积及严重程度指数(Eczema Area and Severity Index,EASI)评分和视觉模拟评分法(Visual Analogue Scale,VAS)评分的总和评分进行疗效评价。结果:两组治疗后第1天各皮损项目评分较治疗前下降(P<0.05),治疗组各皮损项目评分下降幅度优于对照组(P<0.05);治疗组治疗后第60天各皮损项目评分较治疗前仍有明显下降(P<0.05),对照组各皮损项目评分较治疗前无明显下降(P>0.05);治疗组近期、远期疗效总有效率均高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:PRP联合热敏灸治疗能够在行气通络、活血除湿的同时起到促进组织修复,加速疮面愈合,抗炎抗菌的作用,显著降低慢性局限性湿疹皮损评分,改善皮损症状,且复发率低、治疗时间短、经济负担小,可有效改善患者的生活质量,值得临床进一步推广。
